Solutions crafted by NextGenRnD

The R&D solutions crafted by NextGenRnD have a positive, lasting impact on the pipeline of technologies developed by the leading biopharmaceutical companies. The antibody drug conjugate technology R&D solution created by the founder of NextGenRnD has been acknowledged by Debiopharm in the press releases associated with diagnostic and therapeutic antibody conjugation and in multidrug linker platform technologies.

The impact of our mRNA delivery platform R&D solution has been acknowledged (video, 02:47–03:44).

Technology Readiness Level scale, TRL-scale, is an industrially applied concept that outlines the R&D steps required to progress from Basic Research to Applied Research and ultimately to Experimental Development. Basic Research maps to TRLs 1-2, Applied Research maps to TRLs 3-5, and Experimental Development starts at TRL 6.

Ready-made Solutions created by NextGenRnD contain a transition from Basic Research to Applied Research, the transition from TRL 2 to TRL 3. Our ready-made R&D solutions are switches enabling Basic Research to Applied Research transition.

NextGenRnD ready-made solution is:

(1) formulated technology concept corresponding to at least TRL 2.

(2) research proposal with: (a) detailed experimental design and approach to solve the specified R&D problem; (b) limitations and experimental plan to address them. These characteristics make the seamless transition to TRL 3 highly likely.

(3) novel and based on experimental evidence but not yet reduced to practice;

(4) interdisciplinary addressing the problem emerged, emerging, or re-emerging at the intersection of several fields.

Here is an example of a simplified NextGenRnD ready-made solution: Soluble, hydroxypropyl-etherified, β-cyclodextrin (HPβCD) for the removal of phenol group compounds.

What our customers say about our solutions

Thank you for your proposal which has been selected as the best one. The solution proposed will cover and is compatible with all small antibody formats with no anticipated impact on the antigen-binding site.

  • Search & Evaluation and Scientific Innovation Department; Company size: 420+ employees; Headquarters: Switzerland

The solution is very effective under laboratory conditions.

  • R&D Department; Company size: 5000+ employees; Headquarters: USA

We were impressed by the description of the in vitro model and the level of detail provided, including the research plan as well as the underlying expertise.

  • Discovery Research Department; Company size: 50000+ employees; Headquarters: EU

The solution was detailed in the process, modeling and principles of attenuation.

  • External Research and Innovation Department; Company size: 30000+ employees; Headquarters: USA

The solution is very complete and innovative.

  • R&D Department; Company size: 20000+ employees; Headquarters: EU

The solution was extremely detailed and well planned.